Immuron IMRN
NASDAQ IMRN
$1.25 +0.01 (+1.21%)
At close: Sep 22, 2026 · 4:00 PM EDT

Immuron (IMRN) Net Income towards Common Stockholders Growth (5y) (2021 - 2025)

Analysis

Immuron (IMRN) Net Income towards Common Stockholders Growth (5y) (2021 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 212.54 Bn 198.55 Bn 7.24 Bn
2 Gilead Sciences 186.84 Bn 183.58 Bn 6.22 Bn
3 Vertex Pharmaceuticals 129.39 Bn 121.54 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.05 Bn 74.06 Bn 3.93 Bn
5 Moderna 69.00 Bn 63.87 Bn 52.00 Mn
6 Argenx Se 61.15 Bn 55.97 Bn 1.37 Bn
7 Alnylam Pharmaceuticals 32.67 Bn 29.37 Bn 992.69 Mn
8 Biogen 32.37 Bn 31.08 Bn 1.96 Bn
9 Roivant Sciences 28.18 Bn 28.87 Bn 1.16 Mn
10 Immuron 7.25 Mn -1.77 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -11.73%
Dec 31, 2023 56.50%
Dec 31, 2022 -15.92%
Dec 31, 2021 -14.93%
Jun 30, 2021 -14.52%
API Access

Immuron Net Income towards Common Stockholders Growth (5y) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders-growth-5y&ticker=IMRN&period=max&api_key=YOUR_API_KEY